Neuroimmunological characterization of a mouse model of primary progressive experimental autoimmune encephalomyelitis and effects of immunosuppressive or neuroprotective strategies on disease evolution by Buonvicino, D. et al.
Contents lists available at ScienceDirect
Experimental Neurology
journal homepage: www.elsevier.com/locate/yexnr
Research Paper
Neuroimmunological characterization of a mouse model of primary
progressive experimental autoimmune encephalomyelitis and effects of
immunosuppressive or neuroprotective strategies on disease evolution
Daniela Buonvicinoa,⁎, Giuseppe Ranieria, Sara Pratesib, Daniele Guastic, Alberto Chiarugia
a Department of Health Sciences, Section of Clinical Pharmacology and Oncology, University of Florence, Florence, Italy
b Centre of Immunological Research DENOTHE, Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy
c Department of Clinical and Experimental Medicine, Research Unit of Histology & Embryology, University of Florence, Florence, Italy
A R T I C L E I N F O
Keywords:
Progressive EAE
Neurodegeneration
Epitope spreading
Dexamethasone
Mitochondria
Bioenergetics
Bezafibrate
Biotin
A B S T R A C T
Progressive multiple sclerosis (PMS) is a devastating disorder sustained by neuroimmune interactions still wait
to be identified. Recently, immune-independent, neural bioenergetic derangements have been hypothesized as
causative of neurodegeneration in PMS patients. To gather information on the immune and neurodegenerative
components during PMS, in the present study we investigated the molecular and cellular events occurring in a
Non-obese diabetic (NOD) mouse model of experimental autoimmune encephalomyelitis (EAE). In these mice,
we also evaluated the effects of clinically-relevant immunosuppressive (dexamethasone) or bioenergetic drugs
(bezafibrate and biotin) on functional, immune and neuropathological parameters. We found that immunized
NOD mice progressively accumulated disability and severe neurodegeneration in the spinal cord. Unexpectedly,
although CD4 and CD8 lymphocytes but not B or NK cells infiltrate the spinal cord linearly with time, their
suppression by different dexamethasone treatment schedules did not affect disease progression. Also, the
spreading of the autoimmune response towards additional immunogenic myelin antigen occurred neither in the
periphery nor in the CNS of EAE mice. Conversely, we found that altered mitochondrial morphology, reduced
contents of mtDNA and decreased transcript levels for respiratory complex subunits occurred at early disease
stages and preceded axonal degeneration within spinal cord columns. However, the mitochondria boosting
drugs, bezafibrate and biotin, were unable to reduce disability progression. Data suggest that EAE NOD mice
recapitulate some features of PMS. Also, by showing that bezafibrate or biotin do not affect progression in NOD
mice, our study suggests that this model can be harnessed to anticipate experimental information of relevance to
innovative treatments of PMS.
1. Introduction
In spite of the remarkable advancement in the therapeutic arma-
mentarium available to counteract multiple sclerosis (MS) in its relap-
sing-remitting phase, there is still a high need for drugs able to prevent
and/or delay disability worsening in patients affected by primary or
secondary progressive MS (Ciotti and Cross, 2018; Ontaneda and Fox,
2015). Indeed, even the positive results recently obtained in clinical
trials with ocrelizumab (a B cell-depleting anti CD20 antibody) in pa-
tients with primary progressive MS (PPMS) and with siponimod (a se-
lective shingosine-1 and -5 phosphate receptor agonist) in those pre-
senting secondary progressive MS (SPMS) are quantitatively limited
and might be restricted to specific subgroups of MS patients (i.e. short
progression history and substantial CNS inflammatory activity) (Kappos
et al., 2018; Montalban et al., 2017). In keeping with this, the causative
link between the different types of neuroimmune infiltrates and de-
velopment of disease progression is a topic that continues to be highly
debated (Lassmann, 2018). From a pathophysiological point of view, it
makes sense that neurodegenerative events responsible for progression
might be triggered by repetitive cycles of demyelination sustained by
the autoimmune infiltrates (Bjartmar et al., 2003). However, the in-
ability of immunosuppressive drugs to counteract disease progression
(Baldassari and Fox, 2018) suggest a more complex scenario where an
immune-independent component contribute to neurodegeneration (Lee
et al., 2014). The identification of neuroprotective strategies able to
counteract axonal loss might synergize with existing
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immunomodulatory therapies to improve efficacy of progressive MS
treatment.
On this basis, a great deal of effort has been focused at elucidating
the pathogenetic mechanisms underlying neurodegeneration during MS
progression at the cellular and molecular level. There is large consensus
that disability worsening is due to accumulating axonal loss within both
the spinal cord and brain (Bjartmar et al., 2000; Trapp et al., 1998).
Although the precise molecular mechanisms of neurodegeneration are
not without contention (Witte et al., 2019), it has been proposed that a
sort of “virtual hypoxia” promoted by chronic demyelination and de-
rangement of mitochondrial bioenergetics is the main perpetrator of
axonal degeneration (Sedel et al., 2016; Trapp and Stys, 2009). Speci-
fically, demyelinated axons undergo derangement of sodium home-
ostasis that on the one hand increases adenosine triphosphate (ATP)
consumption by the Na+/K+ ATPase, and on the other prompts in-
version of the Na+/Ca2+ transporter and intracellular Ca2+ overload.
The latter further compromises axonal energy dynamic, eventually
leading to oncotic swelling and degeneration (Sedel et al., 2016). Re-
markably, impaired mitochondrial respiration, typically identified in
normal appearing white and gray matter of MS patients (Witte et al.,
2013a), further worsens axonal energy failure. On this basis, there is
large consensus that support of energy dynamics within both demye-
linated and healthy CNS regions may represent a key strategy for
therapeutic intervention during disease progression (Witte et al.,
2013a). However, with the possible exception of biotin (Sedel et al.,
2016), such an approach did not lead to any drug candidate with rea-
listic translational potential to PMS therapy, so far.
With this information in mind, in order to define the therapeutic
potential of mitochondrial active compounds to treatment on MS pro-
gression, we adopted a bedside to bench strategy. Basically, in an an-
imal model of progressive experimental autoimmune encephalomyelitis
(EAE) we planned to test approved drugs known to support cellular
bioenergetics that might be readily translated to treatment of PMS. We
hypothesized that such a repurposing approach on the one hand could
corroborate the relevance of mitochondria as therapeutic targets for
PMS treatment, and on the other might accelerate clinical translation.
In this study, we first evaluated several immune and neuropatho-
logical parameters of NOD mice with EAE in order to find possible si-
milarities with PMS. In these animals, we then studied the effects of two
mitochondrially-active drugs such as bezafibrate, able to promote mi-
tochondriogenesis and organelle functioning by activating the peroxi-
some proliferator-activated receptor (PPAR)γ coactivator-1α (PGC-1α)
axis, and biotin, a well-known vitamin currently evaluated in clinical
trials for PMS therapy but, surprisingly, never tested in EAE models.
2. Materials and methods
2.1. Experimental design
All animal care and experimental procedures were performed ac-
cording to the European Community guidelines for animal care
(European Communities Council Directive 2010/63/EU) and were ap-
proved by the Committee for Animal Care and Experimental Use of the
University of Florence. Female NOD/ShiLtj (6, 8 and 10week old)
purchased from Charles River (Milan, Italy) were housed in a conven-
tional unit (5–6 per cage) with free access to food (Harlan Global Diet
2018, Harlan Laboratories, Udine, Italy) and water, and maintained on
a 12h light/dark cycle at 21 °C room temperature.
2.2. EAE induction and treatment
EAE was induced in NOD/ShiLtj mice by subcutaneous immuniza-
tion, with 250 μg of MOG35–55 peptide (synthesized by EspiKem Srl.,
University of Florence, Italy), emulsified in complete Freund's adjuvant
(CFA) (Sigma, Milan, Italy) containing 4mg/ml of Mycobacterium tu-
berculosis H37RA (Difco Laboratories, Detroit, MI, USA) in the flanks
and at the base of the tail. Immediately thereafter and 48h later, mice
received intraperitoneal injection (i.p.) of 200ng pertussis toxin (PTX)
(Sigma, Milan, Italy) in 100μl Phosphate-Buffered Saline (PBS). Clinical
signs of EAE were examined daily by blinded operators. The following
score were assigned: 0, normal; 0.25 or 0.5, splay reflex test (performed
by lifting the mouse by its tail and observing the degree of hindlimb
splay during 10 s. If both hindlimbs were splayed outward away from
the abdomen, a 0 score was assigned. If one or both hindlimbs were
partially retracted toward the abdomen without touching it, a score
0.25 or 0.5 was assigned, respectively); 1, weakness of the tail/hind
limbs; 2, ataxia and/or difficulty in righting; 3, paralysis of the hind
limbs and/or paresis of the forelimbs; 4, tetraplegia. Because of ethical
reasons, score 4 mice were euthanized as soon as they reached the
score. All the different treatments started at score 1. Bezafibrate and
biotin (Sigma, Milan, Italy) were dissolved in PBS and administrated per
os (oral somministration) on a daily basis at 100 and 50mg/kg body
weight, respectively. Dexamethasone (Sigma, Milan, Italy) was dis-
solved in PBS and administrated per os at 10mg/kg for 5 days or daily at
0.3 mg/kg from score 1. Immunized vehicle-treated animals daily re-
ceived the same amount of PBS.
2.3. Board test
The board test consisted of a 40 cm square plane. Mice were placed
on the center of the board one by one and allowed to move about freely.
Two electric sensors, crossing the plane from midpoint to midpoint of
opposite sides, thus dividing the plane into four equal quadrants, au-
tomatically signaled the movement of the animal on the surface of the
plane. For each mouse is reported the total counts of spontaneous lo-
comotion in 10min (Galeotti et al., 2006).
2.4. Flow cytometry
Mononuclear spleen cells and spinal cord infiltrating leukocytes
were characterized by flow cytometry. Briefly, MOG-immunized NOD
mice were sacrificed at different disease score and perfused with cold
saline prior to organ collection, then a single cell suspension for each
sample was prepared (Cavone et al., 2011; Cavone et al., 2015) and
stained with anti-CD4 FITC, anti-CD8 PE, anti-C45R (B220) APC and
anti-NK 1.1 PerCP-Vio770 or isotype-matched control IgG antibodies
(all from Miltenyi Biotec, Bergisch Gladbach, Germany) according to
the manufacturer's instructions. The cells were then analyzed using a
FACSCanto II flow cytometer (BD Biosciences) equipped with FACSDiva
software (BD Biosciences), acquiring a total of 104 events for spleen
extracts and at least 105 events for spinal cord extracts. 10 week-old
NOD mice were used as control.
2.5. Antigen-dependent T-cell proliferation and ELISA
Cells extracted from lymph nodes, spleen or spinal cord of control or
MOG35–55-immunized mice were cultured in complete RPMI in 96 wells
plates (2×105 cells per well) and stimulated or not with 50 ng/ml
phorbol myristate acetate (PMA) plus 1 μg/ml ionomycin, MOG35–55
(20μg/ml) or MOG8–22 (20μg/ml) (Cavone et al., 2015). After 72 h, the
proliferative response was measured by [3H]thymidine incorporation
test. [3H]Thymidine (1 Ci/well; PerkinElmer) was added and pulsed for
the last 12 h. Plates were then harvested (Tomtec MacIII) on glass fibre
filter (PerkinElmer), and thymidine uptake was measured by liquid
scintillation in a MicroBeta 1450 Trimux counter (Wallac). Super-
natants were collected after 72 h of culture for IFN-γ measurements by
ELISA (Life technologies, Monza, Italy) according to the manufacturer's
instructions. Detection limit for IFN-γ was 5.3 pg/ml.
2.6. Plasma Ab ELISA
Whole blood was collected via cardiac puncture from NOD mice at
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different time points after MOG 35–55 immunization. Samples were
anticoagulated in 10 μl of 50mM EDTA and centrifuged for 5min at
500 rpm. Plasma was removed and frozen at −80oC until assayed.
MOG 35–55 peptide was diluted (10 μg/ml) in bicarbonate coating
buffer (pH 9.0), aliquoted (100 μl/well) into Maxisorb® immunoassay
plates (Nunc/Thermo Fisher Scientific, Rochester, NY, USA) and in-
cubated overnight at 4oC. Plates were blocked for 2 h with 3% BSA/
PBS. After washing with PBST, plasma samples (100 μl) diluted 1:100 or
1:400 in PBS-0.05% Tween-20 were added to wells and incubated for
1 h at room temperature (RT). Wells were washed and incubated with
HRP-labeled antibodies (Jackson ImmunoResearch, West Grove, PA,
USA) versus IgG (diluted 1:40,000) in dilution buffer. Following 1 h
incubation at RT, wells were washed and incubated with 100 μl TMB
substrate solution (Sigma Aldrich) in the dark for 10min. The reaction
was stopped with the addition of 100 μl 2.5 N H2SO4 and the Abs450
was read using a Synergy microplate reader (Biotek, Winooski, VT,
USA) (Liu et al., 2012).
2.7. Histological analysis
Lumbosacral spinal cord from control or MOG-immunized NOD
mice at different times of disease were collected, fixed in 4% paraf-
ormaldehyde in 0.1M PBS, embedded in paraffin and cut into 10 μm
thin section. Axonal loss and myelin loss were assessed by
Bielschowsky's silver staining and Luxol Fast Blue, respectively. Images
were acquired by using an Olympus BX40 microscope (Olympus, Milan,
Italy) and a digital camera (Olympus DP50) with NIS-Elements soft-
ware; sections were analyzed by blinded operator by using ImageJ
software (71 - Schneider CA).
2.8. Quantitative PCR
Genomic DNA was extracted from mice spinal cord with the
NucleoSpin TriPrep kit (Macherey-Nagel, Duren, Germany). Total RNA
from mouse spinal cord was isolated using Trizol Reagent (Life
Technologies). One μg of RNA was retrotranscribed using iScript (Bio-
Rad, Milan, Italy). Real-Time PCR was performed using Rotor-Gene
3000 (Qiagen, Milan, Italy) and the Rotor-Gene TM SYBR® Green PCR
Kit (Qiagen, Milan, Italy), the reactions were run at 95 °C for 30 s, 95 °C
for 5 s and 60 °C for 15 s for 45 cycles. Mitochondrial content was
quantified by measuring the ratio between the mitochondrial Nd1 and
nuclear β-actin gene amplification products (Felici et al., 2017). The
following primers were used: for PGC1-α: forward 5′-GACAGATGGAG
CCGTGACCACTG-3′ and reverse 5′-CTGATCCTGTGGGTGTGGTTTGC-
3; for PPAR-α forward 5′-GGCTCTGTCATCACAGACACCCTCT-3′ and
reverse 5′-GCCGAATAGTTCGCCGAAAGAAGCCC-3′; for mt-Nd2 for-
ward 5′-ATTATCCTCCTGGCCATCGTA-3′ and reverse 5′-AAGTCCTAT
GTGCAGTGGGAT-3′; for Ndufv2 forward 5′-GTGCACAATGGTGCTGG
AGGAG-3′ and reverse 5’-GGTAGCCATCCATTCTGCCTTTGG-3′; for
Atp5d forward 5′-CAGCACGGGCTGAGATCCAGAT-3′ and reverse
5′-GACAGGCACCAGGAAGCTTTAAGC-3′; for Cox1 forward 5′- TATCA
ATGGGAGCAGTGTTTG-3′ and reverse 5′- AGGCCCAGGAAATGTTGAG
-3′; for Cox2 forward 5′- CTGAAGACGTCCTCCACTCAT 0-3′ and reverse
5′- TCTAGGACAATGGGCATAAAG -3′; for Cox15 forward 5′- GTTCTG
AGATGGGCACTGGACCA -3′ and reverse 5′- GGGGCACGTGTTCCTGA
ATCTGT -3′; for 18S forward 5′-AAAACCAACCCGGTGAGCTCCCTC-3′
and reverse 5′-CTCAGGCTCCCTCTCCGGAATCG-3′; for mt-Nd1 forward
5′-TGCCAGCCTGACCCATAGCCATA-3′ and reverse 5’-ATTCTCCTTCT
GTCAGGTCGAAGGG-3′; for β-actin forward 5′-GCAGCCACATTCCCGC
GGTGTAG-3′ and reverse 5′-CCGGTTTGGACAAAGACCCAGAGG-3′.
2.9. Transmission electron microscopy
Transmission electron microscopy was performed as previously
described (Felici et al., 2017). Briefly, spinal cord was fixed in Kar-
novsky's solution, post-fixed in 1% osmium tetroxide and embedded in
Epon 812. Ultrathin sections were stained with uranyl acetate and al-
kaline bismuth subnitrate and examined under a JEM 1010 electron
microscope (Jeol, Tokyo, Japan) at 80 kV. Micrographs were taken at
final magnifications of 15,000× and 80,000× using a MegaView III
digital camera and interfacing software (SIS-Soft Imaging System,
Munster, Germany). To analyze cristae area, only mitochondria un-
equivocally present within axoplasmic fields were analyzed. Areas of
cristae were measured using iTEM image analysis software (SIS).
2.10. ATP measurement
Cellular ATP content was measured by means of an ATPlite kit
based on the production of light caused by the reaction of ATP with
added luciferase and D-luciferin (Perkin Elmer, Milan). Briefly, 70 μl of
luciferase buffer and then 20 μl of D-luciferin was added to cells grown
in a 48 well plate. Cell luminescence was evaluated after 5min by
means of a luminometer (Buonvicino et al., 2018).
2.11. Neuronal cultures
Pure neuronal cultures were prepared by seeding cortical cells ob-
tained from 16 to 18 days old embryos as previously described
(Chiarugi and Moskowitz, 2003). Neurons were cultured in Neuroba-
salTM medium with B-27 supplement (GIBCO) and 0.5 mM glutamine
onto 48 poly-D-lysine-coated (Sigma, Milan, Italy) multiwell plates.
Neurons were plated at a density of 2×105 cells·ml−1 and were used at
7 DIV from preparation.
2.12. Primary oligodendrocyte cultures
Purified cortical oligodendrocyte progenitor cell (OPC) cultures
were prepared as described elsewhere (Fumagalli et al., 2011). Wistar
rat pups (postnatal day 1) were killed and cortices removed, me-
chanically and enzymatically dissociated, suspended in DMEM con-
taining 20% fetal bovine serum (FBS), 4 mM L-glutamine, 1mM Na-
pyruvate, 100 U/ml penicillin, 100 U/ml streptomycin (EuroClone,
Milan, Italy), and plated in poly-D-lysin coated T75 flasks (1 flask per
animal). After 2–3 days in culture, OPCs growing on top of a confluent
monolayer of astrocytes were detached by 6 h horizontal shaking.
Contaminating microglial cells were eliminated by 1 h pre-shake and by
further plating detached cells on plastic culture dishes for 1 h. OPCs,
which do not attach to plastic, were collected by gently washing the
dishes and replated onto 50 μg/ml poly-DL-ornithine-coated (Sigma,
Milan, Italy) 48 multiwell chambers. OPC cultures were maintained in
Neurobasal medium (Invitrogen, Milan, Italy) containing 2% B27,
4mM L-glutamine, 1mM Na-pyruvate, 100 U/ml penicillin, 100 U/ml
streptomycin, 10 ng/ml platelet derived growth factor (PDGF-BB) and
10 ng/ml basic fibroblast growth factor (bFGF) (PeproTech EC Ltd.,
London, UK) to promote cell proliferation. After 2–3 days, cells were
switched to a Neurobasal medium lacking growth factors in order to
allow cell differentiation, and were used after 2–3 days.
3. Results
3.1. Features of MOG35-55-induced EAE in NOD mice
Autoimmunity-prone NOD mice have been used in order to re-
produce a chronic encephalomyelitis [see (Dang et al., 2015) for com-
prehensive review]. Still, most of the studies followed disease evolution
for a short period of time, and there is lack of information on the neuro-
and immunopathological features during the delayed phases of EAE
(Basso et al., 2008; Farez et al., 2009; Huntington et al., 2006; Ichikawa
et al., 2000; Mayo et al., 2016). Also, although neuropathology of im-
mune infiltrates has been reported (Jayaraman et al., 2017), the timing
of CNS immune invasion by the different immune cell types in NOD
mice with EAE waits to be described in detail. We therefore first
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evaluated whether immunization with MOG35-55 at different ages
causes a different disease onset. We found that onset was more rapid
when immunization occurred in 10week old mice (peak onset around
day 20 post immunization), than in 6 or 8 week old mice showing onset
around day 58 ± 8 and 50 ± 7 (mean ± SEM) post immunization,
respectively (n=25 per group, not shown). On this basis, for the rest of
the study we adopted immunization in 10 week old mice. Reportedly,
disease in EAE NOD mice shows a relatively variable evolution, mostly
consisting in a relapsing progressive pattern, sometimes also presenting
an initial, short-lasting acute phase of neurological impairment fol-
lowed by prompt remission and subsequent progression (Dang et al.,
2015). Interestingly, 10 week old NOD mice immunized with MOG35-55
displayed a gradual worsening of neurological disability without evi-
dence of an initial acute phase (representative single mouse disease
evolution patterns are shown in Fig. 1A and Fig. S1). Among 288 NOD
mice immunized in our laboratory, not a single animal recovered or
showed a permanent state of chronic disease. Further, as reported
(Sadelain et al., 1990), NOD mice did not develop diabetes once ex-
posed to the immunization protocol. Indeed, we did not find altered
glycaemia in immunized NOD mice throughout disease evolution (Fig.
S2A).
As for relapses superimposed on progressive neurological wor-
sening, we never found episodes of acute worsening followed by re-
mission. Rather, we noticed that in only 5 out of 90 (5,6%) animals a
single episode of acute, partial remission (at least of 1 point of score
amelioration) superimposed on the progressive pattern of disease evo-
lution occurred (a representative mouse is shown in Fig. 1B). When the
two types of progression where cumulated in a single group, a pattern
of primary progressive EAE (PPEAE) was obtained (Fig. 1C). Also, we
found that incidence was 100% and all the animals reached score 4. To
better appreciate the final stages of progression in these animals, we
followed disease evolution until each animal reached score 4. Un-
expectedly, we found that progression rate was very variable among
mice, and time at which animals reached score 4 ranged from 12 to
122 days after disease onset. Every other day evaluation of mouse
weight revealed that disease onset was not preceded by weight loss and
that the latter occurred from score 2 (Fig. S2B).
3.2. Temporal kinetics of the neuroimmune response in PPEAE NOD mice
To gather information on the qualitative and quantitative aspects of
neuroimmune infiltrates in PPEAE NOD mice at different stages of
neurological impairment, we next evaluated CD8+ and CD4+ T cells,
CD45R+ B cells and NK1.1+ NK cells in their spinal cord and spleen.
As shown in Fig. 2A and B, a progressive, time-dependent increase of
CD8+ lymphocytes occurred from score 1, reaching a ~13-fold
increase at score 2 that then plateaued up to score 4. Similarly, CD4+ T
cells already infiltrated the spinal cord at score 1 and increased up to
score 4 reaching a ~20-fold increment. Interestingly, we found a ten-
dency to increase in CD45R+ B cells that did not reach statistical sig-
nificance at the disease stages analyzed. Similarly, NK cell number did
not show any increase in the spinal cord of NOD mice during EAE
progression (Fig. 2B). When the same cell populations were analyzed in
the spleen, in keeping with the CNS- and epitope-restricted auto-
immune response (see below), any quantitative change was detected
(Fig. 2C). We next investigated whether a MOG-specific antibody re-
sponse occurred during disease progression, and found that serum au-
toantibodies were detectable in mice at day 30 after immunization. The
titer increased along with disease progression although a slight de-
crease was present in sera of score 4 mice (Fig. 2D).
3.3. Evaluation of epitope spreading in PPEAE NOD mice model
To further characterize the immunological events occurring in
PPEAE NOD mice, we next evaluated possible development of an im-
mune response to epitopes distinct from the disease-causing epitope
(so-called “epitope spreading”), during disease evolution. It is well
known that epitope spreading is a key determinant of the different
waves of autoimmune attacks that underlie relapses at the preclinical
and clinical level (McMahon et al., 2005; Quintana et al., 2014). Ac-
cordingly, we recently reported the occurrence of epitope spreading
concomitant with time of relapses in SJL mice (Cavone et al., 2014). We
found that lymphocytes isolated from draining lymph nodes, spleen or
spinal cord of score 4 NOD mice underwent efficient proliferation if
exposed to MOG35–55 but not to an additional, highly immunogenic
peptides such as MOG8-22 (Fig. 3A). In keeping with this, IFNγ was
detected only in the medium of MOG35-55–exposed lymphocytes
(Fig. 3B). We next investigated whether the number of MOG35-55-spe-
cific lymphocytes varies in the spinal cord of PPEAE NOD mice during
disease progression. Notably, we found that MOG-specific lymphocyte
proliferation from spinal cord extracts linearly increased during disease
progression (Fig. 3C), as well as the extent of IFNγ produced in the
mixed lymphocytes reaction (Fig. 3D).
3.4. Neuropathology in PPEAE NOD mice
The progressive worsening of disability in MOG35-55–immunized
NOD mice showing the classic caudo-cranial evolution of en-
cephalomyelitis prompted us to investigate their neuropathological
correlates. As shown in Fig. 4A, we found that demyelination was un-
detectable at score 1, whereas appeared as vacuolized submeningeal
regions of the anterior columns at score 2, progressively broadening to
Fig. 1. Characterization of EAE progression in 10-week-old female NOD mice immunized with MOG35-55.
Evolution of neurological disability in a PPEAE mouse without (A) or with (B) remission. The percentage of mice belonging to the two different progression type is
shown. (C) Cumulative evolution of neurological disability in out of 152 immunized control mice.
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the lateral and posterior columns at score 3 and 4 (Fig. 4A). Im-
portantly, in keeping with the progressive (i.e. irreversible) neurolo-
gical impairment of mice, we also found spinal cord neurodegeneration
(Fig. 4A) showing similar temporal kinetics (Fig. 4B) and spatial dis-
tribution (Fig. S3) of demyelination. Importantly, we have been unable
to find demyelinated regions with spared axons, suggesting that neu-
rodegeneration rapidly occurred upon loss of myelin.
3.5. Mitochondrial parameters in spinal cord of PPEAE NOD mice
Since myelin loss as well as axonal degeneration were both histo-
logically detectable only from score 2, we then attempted to investigate
whether molecular parameters of neuronal homeostasis were altered at
earlier disease stages. According to a well acknowledged hypothesis,
mitochondrial derangement may play a key, causative role in the
pathogenesis of MS progression (Campbell et al., 2011; Dutta et al.,
2006). On this basis, given that mtDNA copy number is a key molecular
parameter of mitochondrial health (Blokhin et al., 2008), we first
analyzed mtDNA content within the mouse lumbar spinal cord of mice
with different degrees of neurological disability. Remarkably, we found
that mtDNA content was already significantly reduced in mice at score
1 and further decreased in animals with a neurological score of 2 and 4
(Fig. 4C). Remarkably, the sole challenge with Freund's adjuvant plus
pertussis toxin did not suffice to alter mtDNA content (Fig. S4). Given
that the mtDNA parameter is inevitably confounded by the glial con-
tribution, we next visualized mitochondria within axons of spinal cord
anterior columns of score 2 mice and found that mitochondria of PPEAE
mice had a pale appearance compared to those of healthy controls
(Fig. 4D). Mitochondrial electron transport impairment typically
prompts transition from the condensed to the orthodox conformation, a
Fig. 2. Characterization of inflammatory infiltrates and plasma Ab in PPEAE NOD mice.
(A) Representative plots of FACS analysis of CD8 and CD4 positive cells harvested at different stages of disease progression from spinal cord MOG35-55-immunized
NOD mice. Quantitation of FACS analysis of CD8, CD4, CD45R (B220) and NK1.1 spinal cord (B) and spleen (C) positive cells harvested from NOD mice at different
stages of disease evolution. (D) Serum MOG-specific antibody response in NOD mice at different stages of disease evolution. Each column is the mean ± SEM of at
least 8 animals per group. In (D) each column is the mean ± SEM of at least 4 animals per group. *p < .05, **p < .01, *** p < .001 vs Control mice (Crl)
(Student's t-test).
Fig. 3. Evaluation of epitope spreading in PPEAE NOD mice model.
Lymphocytes from lymph nodes, spleen and spinal cord of score 4 MOG35-55-immunized NOD mice were re-challenged in vitro with MOG35-55 or MOG8-22 (20 μg/ml),
and proliferation (A) or IFNγ production (B) was evaluated. Lymphocytes proliferation (C) and IFNγ production (D) of spinal cord extract obtained from different
scores of MOG35-55-immunized NOD mice re-challenged with MOG35-55 (20 μg/ml/72 h). In (A) and (B) each column is the mean ± SEM of 4 animals per group.
*p < .05 vs vehicle (PBS) (Student's t-test). In (C) and (D) each column is the mean ± SEM of 3 animals per group. *p < .05 vs Vehicle (PBS) (Student's t-test).
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morphological condition characterized by large and diffuse matrix with
reduced intracristal volume (Perkins and Ellisman, 2011). In keeping
with this, we found that axonal mitochondria had smaller cristae and a
matrix enlarged with a watery appearance (Fig. 4E). We therefore
measured the area of 583 and 524 mitochondrial cristae belonging to
control or score 2 mice, respectively. As shown in Fig. 4F, mitochon-
drial cristae area was significantly reduced in score 2 compared to
control mice. With the aim at identifying the molecular mechanisms
responsible for changes in mitochondrial morphology, in light of the
key role of electron transport flux in determining the condensed-to-
orthodox transition, we focused on respiratory complex subunit ex-
pression. The very high number of mitochondrial respiratory complex
subunits limits the possibility of a detailed transcriptional analysis of all
of them. Thus, we next investigated transcript levels of a limited
number of mitochondrial (Cox1, Cox2, Nd2) and nuclear (Cox15,
NDUFV2 and Atp5d) DNA-encoded respiratory subunits in the spinal
cord of control or PPEAE mice. Interestingly, we found reduced levels of
Nd2 and Atp5d transcript in score 2 mice compared to controls
(Fig. 4G).
3.6. Effects of dexamethasone on disease progression in PPEAE NOD mice
Taken together, the above mentioned findings corroborated the
primary progressive nature of EAE in NOD mice. Clinically, it is well
known that the progressive phase of MS, both primary and secondary, is
characterized by pathogenetic mechanisms in part insensitive to ap-
proved, disease-modifying immunosuppressive drugs (Baldassari and
Fox, 2018). Corticosteroids are among the most notable examples of
drugs that typically loose efficacy when MS turns into the progressive
phase. In this light, we evaluated different treatment schedules with
dexamethasone, one of the most potent corticosteroids typically able to
counteract disease severity in different EAE mouse and rat models
(Donia et al., 2010; Wüst et al., 2008). Acute relapses of MS patients are
treated with high doses of corticosteroids for a limited, typically in the
order of 5 days, period of time (Milligan et al., 1987). In keeping with
this, we adopted the same treatment protocol in EAE NOD mice. As
shown in Fig. 5A, high dose dexamethasone treatment (10mg/kg)
(Wüst et al., 2008) for 5 days did not alter disease progression at early
(score 2 mice) or delayed (score 3 mice) phases of disease progression.
To corroborate evidence that dexamethasone was unable to ameliorate
neurological impairment, we also adopted a chronic treatment schedule
consisting in daily, oral doses of 0.3mg/kg from score 1, a dose regimen
that reportedly is able to ameliorate neurological impairment in nu-
merous EAE models (Donia et al., 2010). At variance with Donia and
colleagues that administered dexamethasone under prophylactic and
early therapeutic regimens, we designed a clinically-relevant treatment
schedule beginning at disease onset (score 1). Fig. 5B shows that even
with this prolonged exposure the drug did not reduce progression rate.
These findings prompted us to ask whether dexamethasone was indeed
able to affect the neuroimmune response in PPEAE NOD mice. We
therefore measured neuroinflammatory infiltrates, and found that
CD4+ lymphocytes were significantly reduced in the spinal cord of
mice exposed to the chronic (15 days) treatment protocol, with B and
NK cells showing a tendency toward decrease that did not reach sta-
tistical significance (Fig. 5C). As further evidence that dexamethasone
was indeed targeting autoreactive lymphocytes, we found that MOG35-
55–dependent of lymphocytes proliferation was significantly reduced in
spleen extracts from PPEAE mice challenged with dexamethasone for
15 days (Fig. 5D).
3.7. Effects of bezafibrate on disease progression in PPEAE NOD mice
The inability of dexamethasone to counteract disease progression
strengthens the primary progressive nature of EAE in NOD mice. In
light of the apparent pathogenetic role of mitochondrial dysfunction in
MS progression, as well as the present findings showing early de-
rangement of mitochondrial homeostasis during PPEAE NOD mice
(Fig. 4C–E), we next attempted to counteract disease progression by
improving mitochondrial dynamics. Several strategies designed to
support mitochondrial homeostasis converge on PGC1α, a key protein
regulating mitochondrial biogenesis and metabolism (Komen and
Thorburn, 2014). We therefore studied the effects of the antidyslipi-
demic drug bezafibrate, a potent inducer of the PPAR-PGC1α axis and
promoter of mitochondrial biogenesis. We designed a treatment sche-
dule beginning at score 1 with daily oral doses of 100mg/kg (Wang
et al., 2017) that equal the dose of 500–600mg adopted in diabetic
patients. As shown in Fig. 6A–C, treatment with bezafibrate did not
affect disease progression, spontaneous locomotion and survival of mice
with PPEAE. To understand whether bezafibrate was indeed improving
mitochondrial homeostasis in PPEAE mice, we next analyzed different
mitochondrial parameters in their spinal cord. We first checked for
evidence that the drug was pharmacodynamically active. Among the
early PPARα–dependent transcriptional effects of bezafibrate, it is
known that it prompts a sort of amplification cycle by inducing ex-
pression of PGC1α and PPARα itself (Augustyniak et al., 2018). Inter-
estingly, we found that transcripts for these two genes were reduced in
the spinal cord of score 2 mice, and bezafibrate treatment restored
expression levels to control values (Fig. 6D). We went on and analyzed
whether mitochondrial parameters found deranged in PPEAE mice were
also restored by bezafibrate. We found that drug treatment was unable
to counteract reduction of mtDNA copy number (Fig. 6E) but sufficed to
prevent reduction of mitochondrial cristae area (Fig. 6F and G), the
latter being a parameter that can be reliably ascribed to axons. When
the impact of bezafibrate on expression levels of mitochondrial re-
spiratory subunits was evaluated, we found that drug treatment re-
stored Atp5d transcripts to control values, having no effects on those of
Cox1, Cox2, Nd2, NDUFV2 and Cox15 (not shown). Collectively, these
findings indicate that activation of the PPARα-PGC1α axis occurs in
mice with PPEAE even though the ensuing partial restoration of mi-
tochondrial homeostasis by bezafibrate does not translate into neuro-
logical improvement. These findings therefore question the transla-
tional potential of bezafibrate-like drugs in the treatment of MS
progression.
3.8. Effects of biotin on disease progression in PPEAE NOD mice
Biotin, or vitamin B7, is the co-enzyme of several carboxylases also
operating in mitochondria at the tricarboxylic acid cycle (Tong, 2013).
By so doing, biotin might sustain energy production within the CNS
(Ochoa-Ruiz et al., 2015), and may also support ATP production in
Fig. 4. Neurodegeneration in spinal cord of PPEAE NOD mice.
(A) Representative Luxol Fast Blue or Bielschowsky stained spinal cord sections of MOG35–55-immunized NOD mice at different scores. (B) Quantitation of Luxol Fast
Blue or Bielschowsky staining of spinal cord sections of PPEAE mice at different stages of disease. (C) mtDNA content in the spinal cord of PPEAE at different stages of
neurological impairment. (D) Representative electron micrographs (Mag; 15 K) of anterior spinal cord columns of control and score 2 PPEAE mice. Note the pale
appearance of mitochondria in PPEAE mice. (E) The reduced mitochondrial cristae area (Mag; 80 K) in the anterior spinal cord columns of score 2 PPEAE mice
compared to those of control animals is shown in (E) and quantitated in (F). (G) mRNA levels of mitochondrial (Cox1, Cox2, and Nd2) and nuclear (NDUFV2, Cox15,
and Atp5d) respiratory complex subunits in the spinal cord of control or score 2 PPEAE mice. In (B) each column is the mean ± SEM of 20 sections (5 sections/
mouse, n=4 per group). In (C) and (G) each column is the mean ± SEM of 8 animals per group. In (F) 583 and 524 mitochondrial cristae area belonging to control
or score 2 mice were measured. *p < .05, **p < .01, ***p < .001 vs Control mice (Student's t-test). (For interpretation of the references to colour in this figure
legend, the reader is referred to the web version of this article.)
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neurons exposed to virtual hypoxia (Sedel et al., 2016). Accordingly,
daily oral biotin reduced progression of disability in two clinical trials
that collectively enrolled>250 PMS patients (Birnbaum and Stulc,
2017; Tourbah et al., 2018). Still, to the best of our knowledge biotin
has been tested neither in preclinical PMS models nor in in vitro settings
aimed at investigating its bioenergetic or cytoprotective effects on
neural cells. We therefore first checked whether biotin increases ATP in
cultured mouse cortical neurons, and found that it did not affect ATP
content at 10 and 100 μM, and, surprisingly, reduced them at 1mM
(Fig. 7A). Similarly, the vitamin at 100 μM was unable to afford pro-
tection from glutamate-dependent excitotoxicity (100 μM/24 h)
(Fig. 7B), a type of cell death involved in neurodegeneration during MS
(Pitt et al., 2000), and amplified by early bioenergetic failure (Matute
et al., 2001). Similarly, when tested in cultures of primary rat oligo-
dendrocytes, biotin reduced ATP at 1mM (Fig. 7C), and at 100 μM did
not counteract cytotoxicity induced by the demyelinating agent cupri-
zone (50 μM/6 h) (Fig. 7D). Unfortunately, these negative results were
also confirmed in vivo. Indeed, with a post-treatment protocol (from
score 1) and daily oral dose of 50mg/kg bioequivalent to that adopted
in PMS patients (Tourbah et al., 2018), biotin treatment did not affect
disability progression (Fig. 7E), spontaneous locomotion (Fig. 7F) or
survival (Fig. 7G) in PPEAE mice. Finally, we also asked whether biotin
might somehow affect the extend of neuroinflammatory infiltrates, but
found that PPEAE mice exposed to the vitamin had the same number of
T, B and NK cells in the spinal cord compared to animals receiving
vehicle (Fig. 7H).
4. Discussion
The present study furthers our understanding of EAE in NOD mice
and show that, akin to PMS, it is featured by progressive accumulation
of disability, early mitochondrial dysfunction, substantial neurodegen-
eration and insensitivity to corticosteroids.
Literature about animal models of PMS is somehow confounding.
For instance, analysis of EAE evolution in Biozzi mice as a PMS model
reveals that animals undergo a stable rather than progressive disease
(Lassmann and Bradl, 2017). Also, how EAE in NOD mice strictly re-
capitulates PMS features has never been carefully demonstrated. In
particular, a detailed qualitative and quantitative analysis of neu-
roimmune infiltrates as well as their temporal relationship with disease
evolution still waited to be shown. At variance with prior work showing
a first remission phase in NOD mice followed by disease progression
Fig. 5. Effects of dexamethasone on disease progression in PPEAE NOD mice.
Effects of (A) two, high dose (10mg/kg) or (B) chronic (0.3mg/kg) oral dexamethasone (DEX) treatments on disease evolution of PPEAE mice. (C) Quantitation by
FACS analysis of CD8, CD4, CD45R (B220) and NK1.1 positive cells from spinal cord of vehicle- or dexamethasone (0.3 mg/kg/15 days) treated mice. (D) Mixed
lymphocyte proliferation of spleen extracts obtained from vehicle- or dexamethasone (0.3mg/kg/15 days) treated PPEAE mice, re-challenged with MOG35-55 (20 μg/
ml/72 h). Each point/column represents the mean ± SEM of 9 (Vehicle) and 10 (DEX) animals per group. *p < .05, **p < .01 vs Vehicle (Student's t-test).
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(Dang et al., 2015), we show here a primary progressive pattern of
disease evolution. At present, we are unable to provide an explanation
for such finding, but it is worth noting that we immunized 288 mice and
none showed an early remission phase. We also report that neu-
roimmune invasion linearly increases with time and parallels severity of
disease evolution. We believe that this is a key finding of the present
study. Indeed, in RREAE models such as that of SJL mice, the auto-
immune attack to the CNS massively occurs in the first phase of the
disease and then follows with waves of reduced intensity that, re-
markably, shortly anticipate disease relapses (Cavone et al., 2015). The
kinetics of infiltrates found in NOD mice, therefore, are original and not
consistent with those found in RREAE mice. Rather, we reason that the
slow, progressive increase of immune infiltrates in NOD mice might
represent, at least in part, an inflammatory process secondary to disease
evolution. Obviously, this interpretation is at odds with evidence that
PPEAE is triggered by primary sensitization to a myelin antigen. Also,
the strict temporal and spatial relationship between demyelination and
axonal damage we found in PPEAE NOD mice suggests primary myelin
loss as causal to neurodegeneration. Still, three key findings of the
present study support the hypothesis that neurodegeneration is a
Fig. 6. Effects of bezafibrate on disease progression in PPEAE NOD mice.
Effects of daily, oral treatment with bezafibrate (100mg/kg from score 1) on neurological score (A), spontaneous locomotion (B) and survival (C) in PPEAE NOD
mice. mRNA levels of PGC1α and PPARα (D) or mtDNA content (E) in the spinal cord of control or PPEAE mice (score 2) treated or not with bezafibrate (from score 1
to score 2). The effect of bezafibrate treatment on mitochondrial cristae area (Mag; 80 K) in the anterior spinal cord columns of score 2 PPEAE mice is shown in (F)
and quantitated in (G). In (D-F) mice treated with bezafibrate at least for 30–35 days were used only. In (A), (B) and (C) 20 animals per group. In (D) and (E), each
column is the mean ± SEM of 6 animals per group. In (G) 524 and 564 mitochondrial cristae area belonging to score 2 PPEAE or PPEAE plus bezafibrate mice were
measured. *p < .05, ***p < .001 vs Crl or EAE/beza. ANOVA plus Tukey's post hoc test.
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process somehow independent from neuroinflammation in NOD mice.
First, two different dexamethasone treatment paradigms analogues to
those counteracting EAE in different mouse strains (Donia et al., 2010)
did not affect disease evolution in PPEAE NOD mice in spite of evidence
that the drug reduced both spinal cord immune infiltrates and lym-
phocyte proliferation to MOG. Second, we found that mtDNA copy
number, a prototypical index of mitochondrial functioning, is already
reduced at score 1 when CNS immune infiltrates are minimal and
Fig. 7. Effects of biotin on disease progression in PPEAE NOD mice.
(A) Effect of biotin on ATP contents of cultured primary mouse cortical neurons after 6 or 24 h incubation. (B) Effects of biotin (100 μM) on viability (MTT reduction)
of cultured primary mouse cortical neurons exposed to glutamate (100 μM/24 h). (C) Effect of biotin on ATP contents of cultured primary rat oligodendrocytes after 6
or 24 h incubation. (D) Effects of biotin (100 μM) on viability (MTT reduction) of cultured primary rat oligodendrocytes exposed to cuprizone (50 μM/6 h). Effects of
daily treatment with biotin (50mg/kg from score 1) on neurological score (E), spontaneous locomotion (F) and survival (G) of PPEAE mice. (H) Quantitation by FACS
analysis of CD8, CD4, CD45R (B220) and NK1.1 positive cells harvested from spinal cord of control or PPEAE mice treated or not with biotin. In (A-D) each column
represents the mean ± SEM of three experiments conducted in triplicate. In (E-G) 20 animals per group were used. In (H) each bar represents the mean ± SEM of 5
mice. *p < .05, **p < .01, ***p < .001 vs control/vehicle. ANOVA plus Tukey's post hoc test.
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neurodegeneration is not detectable. This suggests that neurodegen-
eration originates from primary dysfunctional homeostasis within
neural cells and seems not be a consequence of the prolonged neu-
roinflammatory response. We also show condensed to orthodox mi-
tochondrial transition, decrease of cristae area, as well as reduced
transcripts for respiratory complex subunits in the spinal cord of PPEAE
NOD mice. Remarkably, these findings are in keeping with derange-
ment of transcriptional homeostasis of respiratory complexes as well as
mtDNA mutations found in the CNS of PMS patients (Campbell and
Mahad, 2018). Third, lack of spreading toward MOG8-22 in PPEAE NOD
mice, suggests that compared to RREAE SJL mice (Cavone et al., 2014),
accumulation of immune cells in their CNS might not be due to su-
perimposed waves of autoreactive lymphocytes. In this light, our find-
ings suggest that the slow accumulation of T cells found in immunized
NOD mice is, at least in part, driven by autonomous, self-sustaining
neurodegenerative events that, at a certain time point of disease evo-
lution, take over the primary autoimmune response in terms of disease
pathogenesis. This interpretation is corroborated by the notion that the
sole pertussis toxin (i.e. without MOG35–55 challenge) suffices to trigger
EAE in NOD mice (Winer et al., 2001), as well as with evidence of
neurodegeneration in the absence of inflammation in cortical plaques of
PMS patients (Peterson et al., 2001; Vercellino et al., 2005; Wegner
et al., 2006). Of course, identification of the mechanisms operating the
pathogenetic shift from autoimmunity to self-sustaining neurodegen-
eration, as well as their timing, would be instrumental to decipher the
molecular basis of EAE/MS progression.
We also originally report that neither bezafibrate nor biotin was
able to alter disease evolution in PPEAE NOD mice. Of note, both drugs
are routinely used in the clinic and might have had a remarkable
translational potential. Reportedly, bezafibrate promotes mitochon-
driogenesis and a transcriptional response that supports mitochondrial
functioning (Noe et al., 2013). In keeping with this, the drug restored
homeostasis of both PGC1α and PPARα transcripts as well as mi-
tochondrial cristae morphology (a parameter directly related to bioe-
nergetic efficiency of the organelles) in PPEAE mice, indicating that it
was pharmacodynamically active. Notably, the reduced transcript le-
vels of PGC1α we found in PPEAE NOD mice is consistent with the
diminished PGC1α expression in the brain cortex of PMS patients (Witte
et al., 2013a; Witte et al., 2013b). However, evidence that bezafibrate
did not affect disease evolution indicate that the sole impact on mi-
tochondrial dynamics do not suffice to counteract the complex events
responsible for neurodegeneration and disease progression. Data,
therefore, on the one hand corroborate evidence that PGC1α activity is
dysfunctional in PPEAE and PMS, but on the other weaken its relevance
as a PMS therapeutic target.
As for biotin, the inability to counteract disease evolution is of
particular relevance in light of its current testing in patients with pro-
gressive MS. In spite of contrasting findings obtained in recently-con-
cluded trials, and its current sperimentation in a large phase III trial
including patients with primary or secondary progressive MS
(Birnbaum and Stulc, 2017; Tourbah et al., 2018), information on the
effects of biotin in preclinical models of MS is lacking. Of note, in our
study we exposed EAE NOD mice to chronic treatment with an oral dose
of 50mg/kg that corresponds to a human equivalent dose of 291mg,
consistent with that of 300mg adopted in PMS patients (Tourbah et al.,
2018). Even though this dose appears excessive if one considers the
human biotin daily need of 30 μg (Riveron-Negrete and Fernandez-
Mejia, 2017), chronic treatment in NOD mice was safe and well toler-
ated. It is also worth noting that, at variance with the claim that biotin
boosts bioenergetics by promoting Kreb's cycle efficiency, we have been
unable to find any effect of the vitamin on ATP content in primary
cultures of both cortical neurons and oligodendrocytes. These findings,
along with our data showing that biotin does not increase resistance of
neurons to excitotoxicity or of oligodendrocytes to cuprizone, are in
keeping with its inability to reduce disease progression in PPEAE NOD
mice, as well as with work showing worsening of PMS patients on high
dose biotin (Birnbaum and Stulc, 2017). The estimated completion date
of the current multicenter clinical trial with biotin in PMS is September
2019 (http://clinicaltrials.gov, NCT02936037). At that time it will be
possible to learn whether our negative results on biotin were predictive
of clinical failure. This information will also corroborate the relevance
of the PPEAE NOD mouse model as a reliable tool to identify efficacious
treatments for MS progression.
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.expneurol.2019.113065.
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